Your browser doesn't support javascript.
loading
Care Management and Survival of Patients Diagnosed with Synchronous Metastatic Colorectal Cancer: A High-Resolution Population-Based Study in Two French Areas.
Mulliri, Andrea; Gardy, Joséphine; Cariou, Mélanie; Launoy, Guy; Robaszkiewicz, Michel; Alves, Arnaud; Bouvier, Véronique; Dejardin, Olivier.
Afiliação
  • Mulliri A; ANTICIPE U1086 INSERM-UCN, Centre François Baclesse, 14000 Caen, France.
  • Gardy J; Department of Digestive Surgery, University Hospital of Caen, Avenue de la Côte de Nacre, CEDEX, 14033 Caen, France.
  • Cariou M; ANTICIPE U1086 INSERM-UCN, Centre François Baclesse, 14000 Caen, France.
  • Launoy G; Calvados Digestive Cancer Registry, University Hospital of Caen, 14000 Caen, France.
  • Robaszkiewicz M; Finistere Digestive Cancer Registry, University Hospital of Brest, CEDEX, 29200 Brest, France.
  • Alves A; ANTICIPE U1086 INSERM-UCN, Centre François Baclesse, 14000 Caen, France.
  • Bouvier V; Calvados Digestive Cancer Registry, University Hospital of Caen, 14000 Caen, France.
  • Dejardin O; Epidemiology Research and Evaluation Unit, Department of Research, University Hospital of Caen, Avenue de la Côte de Nacre, CEDEX, 14033 Caen, France.
Cancers (Basel) ; 14(7)2022 Mar 31.
Article em En | MEDLINE | ID: mdl-35406549
Population-based studies provide the opportunity to assess the real-world applicability of current clinical practices. The present research evaluated the survival outcomes of different therapeutic strategies for colorectal cancer (CRC) with synchronous metastasis (SM). The differential impact of treatment sequence, viz. whether chemotherapy (CT) or primary tumor resection (PTR) was performed first, was also evaluated. METHODS: All CRC cases with SM diagnosed between 2006 and 2016 (N = 3062) were selected from two specialized digestive cancer registries from northwest France. Cox regression analysis was used to assess survival. Multivariable logistic regression was used to examine factors related to the combination of PTR and CT. RESULTS: The longest survival was observed in patients treated by PTR combined with CT (Group 4; N = 1159). Overall survival was 51.80% at one year (95% Confidence Interval (CI) 50.00-53.60%) and 9.40% at five years (95% CI, 8.30-10.60%). Survival did not differ with respect to the order of treatment in multivariable analysis (hazard ratio, 1.05; 95% CI, 0.88-1.24; p = 0.55). CONCLUSION: Regardless of the sequence of treatment, a PTR + CT offered the best survival in patients with CRC and SM, even though few were eligible for combination therapy (38%).
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França